You are viewing the site in preview mode

Skip to main content


Figure 2 | BMC Infectious Diseases

Figure 2

From: Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals

Figure 2

Treatment cost per SVR (total costs were divided by the corresponding absolute numbers of SVR achieved or expected). NOTE: Cost 1 represents the actual cost incurred for treating the 104 patients under study with Peg-interferon and ribavirin while naïve. Cost 2 represents the estimated cost of a lead-in strategy with PEG-IFN/RBV for 4 weeks, followed by a directly acting antiviral for 12 or 36 weeks in the same patients while naïve. Cost 3 represents the estimated cost of PEG-IFN/RBV in naïve patients (Cost 1) plus PEG-IFN/RBV with addition of a DAA in our patients who did not achieve a SVR.

Back to article page